Preladenant + Placebo + Anticholinergic agents or propanolol + Haloperidol
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Akathisia, Drug-Induced
Conditions
Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
Trial Timeline
Aug 15, 2007 → Jan 9, 2009
NCT ID
NCT00693472About Preladenant + Placebo + Anticholinergic agents or propanolol + Haloperidol
Preladenant + Placebo + Anticholinergic agents or propanolol + Haloperidol is a phase 2 stage product being developed by Merck for Akathisia, Drug-Induced. The current trial status is terminated. This product is registered under clinical trial identifier NCT00693472. Target conditions include Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders.
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00693472 | Phase 2 | Terminated |
Competing Products
1 competing product in Akathisia, Drug-Induced
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Preladenant + Placebo | Merck | Phase 2 | 27 |